GTBP · GT Biopharma Inc. Common Stock
View on chartInsiders & Stakes
| Breen Michael Martin Director | ▲ Buy | Grant | 856,218 Shares held | 8/11/2023 | View profile |
| Wendel Bruce | ▲ Buy | Grant | 352,655 Shares held | 2/16/2021 | View profile |
| Manu Ohri CFO & Secretary | ▼ Sell | Other | 300,000 Shares held | 8/11/2023 | View profile |
| Berk Gregory | ▲ Buy | Grant | 278,058 Shares held | 2/16/2021 | View profile |
Transaction History
| Breen Michael Martin | ▲ Buy | Grant | 200,000 | $57K | 8/11/2023 |
| Manu Ohri | ▲ Buy | Grant | 200,000 | $57K | 8/11/2023 |
| Manu Ohri | ▼ Sell | Other | 200,000 | $57K | 8/11/2023 |
| Manu Ohri | ▼ Sell | Other | 200,000 | $57K | 8/11/2023 |
| Breen Michael Martin | ▲ Buy | Open Market | 50,000 | $25K | 4/11/2023 |
| Manu Ohri | ▲ Buy | Open Market | 50,000 | $25K | 4/6/2023 |
| Manu Ohri | ▼ Sell | Other | 100,000 | $0 | 7/15/2022 |
| Breen Michael Martin | ▲ Buy | Grant | 278,058 | $0 | 7/15/2022 |
| Manu Ohri | ▲ Buy | Grant | 100,000 | $0 | 7/15/2022 |
| Manu Ohri | ▼ Sell | Other | 100,000 | $0 | 7/15/2022 |
| Breen Michael Martin | ▼ Sell | Other | 40,243 | $137K | 2/25/2021 |
| Breen Michael Martin | ▼ Sell | Other | 9,859 | $34K | 2/25/2021 |
| Wendel Bruce | ▲ Buy | Grant | 347,572 | $0 | 2/16/2021 |
| Berk Gregory | ▲ Buy | Grant | 278,058 | $0 | 2/16/2021 |
| Breen Michael Martin | ▲ Buy | Grant | 278,058 | $0 | 2/16/2021 |
| Wendel Bruce | ▲ Buy | Open Market | 1,374 | $12K | 12/22/2020 |
| Wendel Bruce | ▲ Buy | Open Market | 441 | $4K | 12/22/2020 |
| Wendel Bruce | ▲ Buy | Open Market | 3,268 | $10K | 11/16/2020 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
GT Biopharma Files Prospectus for Up to 13.5M Shares
GT Biopharma Inc. has filed a prospectus that allows up to 13,502,835 shares of its common stock to be sold by existing shareholders. This filing gives the company and its investors a formal framework for a potential share sale. The prospectus does not change the company’s current operations or financial outlook. Investors can review the details to understand how the sale could affect share supply.
GT Biopharma Files Prospectus for Up to 13.5M Shares. GT Biopharma Inc. has filed a prospectus that allows up to 13,502,835 shares of its common stock to be sold by existing shareholders. This filing gives the company and its investors a formal framework for a potential share sale. The prospectus does not change the company’s current operations or financial outlook. Investors can review the details to understand how the sale could affect share supply.